***Human immunodeficiency virus (HIV)***

Laboratory case definition

The Public Health Laboratory Network (PHLN) has developed standard case definitions to inform the diagnosis of key diseases in Australia. This document contains the laboratory case definition (LCD) for *human immunodeficiency virus.*

|  |  |  |  |
| --- | --- | --- | --- |
| Version | Status | Authorisation | Consensus Date |
| 1.1 | Updated supplemental serology requirements | PHLN | 2 February 2025 |
| 1.0 | Initial PHLN Laboratory Case Definition | PHLN | February 2022 |

# PHLN summary laboratory definition

## Condition

*Human Immunodeficiency Virus* (HIV) infection

### Definitive Criteria for confirmed case - Children aged >18 months and adults

Repeatedly reactive HIV antibody or HIV antigen/antibody combination assay

AND

* Positive HIV-1/2 differentiation assay or western blot immunoassay

OR

* Detection of HIV nucleic acid (RNA or DNA) by an HIV nucleic acid test

### Definitive Criteria for a confirmed case - Children aged <18 months

* Detection of HIV nucleic acid (RNA or DNA) by an HIV nucleic acid test, on two separate specimens collected on different days

### Suggestive criteria for a probable case - Children aged >18 months and adults

* Detection of HIV nucleic acid (RNA or DNA) by an HIV nucleic acid test

### Suggestive criteria for a probable case - Children aged <18 months

* Detection of HIV nucleic acid (RNA or DNA) by an HIV nucleic acid test

### Special considerations and guide for use

* Consistent with international guidelines, diagnostic confirmation of an AIDS-defining condition without definitive laboratory evidence of HIV infection is insufficient to classify an individual as HIV-infected.
* Some rapid HIV tests have been registered on the ARTG for use at point-of-care (POC). The definitive and suggestive criteria for a confirmed or probable case apply to laboratory tests only, not POC tests.

## Links to related documents

* CDNA (clinical) case definitions: [HIV case definition](https://www.health.gov.au/resources/publications/human-immunodeficiency-virus-hiv-individual-aged-18-months-or-older-surveillance-case-definition?language=en)
* NPAAC ; [Requirements for laboratory testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) Fourth Edition 2023](https://www.safetyandquality.gov.au/sites/default/files/2023-04/requirements_for_laboratory_testing_for_human_immunodeficiency_virus_and_hepatitis_c_virus_fourth_edition.pdf)

# Introduction

Human Immunodeficiency Virus has two known subtypes - HIV-1 and HIV-2, of which HIV-1 causes the overwhelming majority of infections in Australia, where the only known reservoir is humans. The viruses are enveloped plus-stranded RNA viruses within the family retroviridae. HIV-1 was isolated from a patient in 1983, and HIV-2 was reported in 1986. HIV-1 is subdivided into four genetic groups M (subtypes A-K), O, N and P while HIV-2 has eight subtypes (A-H).

HIV-1 has been reported globally, while HIV-2 has remained limited primarily to West Africa and to migrants from West Africa. Both HIV-1 and HIV-2 are most commonly transmitted sexually, but vertical transmission is a common method of transmission in developing countries. Infection may occur through parenteral means including inoculation of infected blood through sharing of contaminated needles or equipment, transfusion of infected blood products, and transplantation of infected tissues.

The natural history of infection is divided into three phases. Acute retroviral syndrome occurs two to six weeks post exposure, presenting with fever, maculopapular rash, oral ulcers, lymphadenopathy, malaise, weight loss, arthralgia, night sweats, or pharyngitis, with an associated high HIV viral load. The second clinical phase of infection is clinical latency, which is usually several years or more without symptoms. The third phase is Acquired Immune Deficiency Syndrome (AIDS) where the patient presents with either opportunistic infections or certain cancers, characterized virologically by high viral loads and low CD4 T-cell counts, typically < 200 cells/mm3. There are over 20 clinical syndromes identifying AIDS in HIV-infected individual globally with the most common being Pneumocystis jirovecii pneumonia, HIV wasting syndrome and oesophageal candidiasis. However in Australia, earlier identification and treatment have changed this spectrum considerably.

HIV infection is commonly diagnosed via detection of HIV antibody using a test that includes antigen and antibody targets, with confirmation using a supplemental test. The assays detecting antigen and/or antibody (Ag/Ab “combo” tests), are currently the predominant assays used in patient screening/testing. HIV antibody becomes detectable approximately 3 weeks after infection whereas p24 antigen becomes transiently detectable from one to two weeks after infection until anti-p24 antibody is produced a week or two later. Qualitative NAT assays, which diagnose and characterise HIV viraemia, are the first tests to become detectable in acute HIV infection, usually around one week after infection. They are used as part of tissue and blood donation screening as well as part of patient laboratory screening algorithms.1 To be used as an HIV diagnostic test in Australia the HIV NAT (qualitative or quantitative) must be registered on the Therapeutic Goods Administration (TGA) Australian Register of Therapeutics Goods (ARTG) as a class 4 *in vitro* diagnostic medical device (IVD). Quantitative viral load assays measure the quantity of HIV-1 or HIV-2 RNA in plasma or in whole blood as surrogate prognostic markers, to monitor therapy, and to determine infectiousness. HIV NAT assays may be registered on the ARTG as dual class 4 qualitative and quantitative assays.

Australian laboratories operate using instrument-based assays, under quality management systems monitored with quality assurance programs from the Royal College of Pathologists of Australia Quality Assurance Program (RCPAQAP) or the National Serology Reference Laboratory (NRL) to regularly check performance. All first-time positive HIV diagnoses should be confirmed with a second independent sample to exclude any pre-analytical (patient labelling) or laboratory error.

HIV is a notifiable disease in all Australian states and territories with similar, although not identical, mechanisms of notification.

# Laboratory diagnosis

## Test regulation

HIV diagnostic tests are referred to as IVDs by the TGA. The system for regulation of IVDs in Australia is risk based. HIV is considered to be a disease that poses high risk to individuals and to the public and therefore, HIV diagnostic tests are assigned to class 4, the highest risk class of the TGA IVD Framework.2 This means that tests to diagnose HIV infection are assessed to the highest stringency of performance. Tests that are used for monitoring or characterising HIV infection once it has been diagnosed are assigned as Class 3 IVD’s from a regulatory perspective. Once a test is assessed as appropriate for its intended use in Australia, it is registered on the ARTG.3

## Serological Tests

The serological tests for establishing HIV infection in an individual are referred to as either screening or supplemental (confirmatory) tests. The format of screening serological assays is commonly enzyme-linked immunoassay (EIA) or chemiluminescent immunoassay (CIA) where both HIV antigen and antibody is detected, but not reported separately. Common applications for serological testing for HIV are for primary diagnosis, screening of blood products, organ and tissue donor screening, management of women when pregnant, in labour and delivery, evaluation of occupational exposure to blood or body fluid, and epidemiological purposes. There are many commercial serology assays available in Australia suitable as HIV-screening tests, please refer to the ARTG3 for individual test details. Supplemental testing involves confirmation of a repeatedly reactive serology screening test result using either a serological test able to differentiate between HIV-1 and HIV-2, or direct virus detection using either virus core (capsid) protein (p24 antigen) testing or HIV nucleic acid testing (NAT). Note that dedicated p24 antigen tests are currently not available in Australia.

## HIV-1 and HIV-2 antigen and antibody screening tests

Following infection with HIV-1, p24 antigen appears in the blood within two to three weeks, around the time of seroconversion illness which occurs in 40–48% of affected individuals. Viraemia then antigenemia precedes the appearance of antibody by up to two weeks. In some individuals, serological assays may show delayed seroconversion, especially with the use of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or prompt antiretroviral therapy.4

Early screening tests were designed to detect antibody to HIV. The HIV combo tests, are fourth generation immunoassays, so named because they detect both HIV-1 antigen and HIV-1/2 antibody using recombinant and/or synthetic antigens simultaneously in serum and plasma. These combo assays are now used for screening in most centres and have been shown to detect infection earlier than tests that detect antibody alone. The assays are easily performed, robust, automated and have high throughput with short turnaround times.

In almost all cases a negative combo assay six weeks after an exposure excludes HIV infection, but a test at 12 weeks post-exposure is recommended. The occurrence of a second diagnostic window (between loss of detectable antigen before the appearance of detectable antibody) with certain 4th generation HIV assays has been reported.5 False positive results can occur infrequently with screening tests, and hence screening test results should be reported as reactive rather than positive. Most manufacturers of HIV screening assays recommend samples that are initially reactive be retested in duplicate in the same assay to confirm the result, as part of NPAAC guidelines.6 Specimens reactive on retesting are referred to as repeat reactors. Repeat reactors on combo assays are then tested on supplemental assays, such as a serological differentiation immunoassay,a p24 antigen-specific assay, and a HIV NAT. HIV NAT can be positive before the appearance of p24 antigen or HIV antibody. It is recommended that all newly diagnosed patients have a repeat test on a second blood sample collection.7

## HIV supplemental serological assays

Following a repeatedly reactive HIV-1/2 screening result confirmation of the antibody and/or antigen reactivity is required. Serological tests with higher specificity than the screening assay and using a different testing format, together with the ability to differentiate between HIV-1 and HIV-2 infection are recommended for this purpose. The ARTG currently lists two types of Class 4 serological assays for this diagnostic purpose, the Geenius™ HIV 1/2 immunochromatographic test (ICT), and the Western blot immunoassay (WB). These assays are known as differentiation assays as, unlike the screening assays, they are able to distinguish antibodies to HIV-1 and HIV-2 antigens. Positivity in these assays is defined based on the number and combination of reactions to individual antigens. However, these assays may not always provide a definitive result. Cross-reactivity between the HIV-1 and HIV-2 bands can occur when infected with either HIV-1 or HIV-2, and the assays can occasionally produce indeterminate results in both HIV-infected and HIV-noninfected individuals. In these cases a HIV NAT is recommended. If the HIV NAT is negative repeating the immunoassay after 2 to 4 weeks is recommended. Although dual HIV-1/HIV-2 infections have been rarely reported most cases with dual reactivity to the HIV-1 and HIV-2 bands represent HIV-1 infection with cross-reactivity to HIV-2 antigens. These assays should not be used as screening immunoassays as they have not been validated for this purpose.

### Geenius™ HIV 1/2 Assay

This is a rapid qualitative ICT for fingerstick or venous whole blood, serum and plasma. Previously the Multispot HIV-1/HIV-2 assay ICT was available to assess for individual reactivity to an HIV-1 gp41 envelope glycopeptide, an HIV-2 gp36 envelope glycopeptide, and a second recombinant HIV-1 gp41 envelope glycopeptide, along with a procedural control spot. The test was read manually by the colour development to each ‘spotted’ antigen. The Multispot assay was shown to detect HIV-1 antibodies earlier than the WB, and reduce indeterminate results, while still identifying HIV-2 infections. However, this assay is no longer available in Australia. The Geenius™ HIV 1/2 Assay employs HIV-1 (p31, gp160, p24, gp41) and HIV-2 antigens (gp36, gp140), which are bound to the membrane solid phase as a band or line, with a control (protein A) line that binds IgG. The test requires only 15 mcL (whole blood) or 5 mcL (serum, plasma). The patient sample, followed by a buffer, is inoculated and migrates along the test strip by lateral flow. Reactivity of antibodies bound to the immobilised antigens is determined by binding of protein A, which is conjugated to colloidal gold dye particles. Pink/purple lines after 20 to 30 minutes incubation at room temperature (180C to 300C) indicate a reactive sample, which can be read manually or with an automated proprietary reader. A positive HIV-1 sample requires two of the four HIV-1 bands being reactive, with one of these bands being either gp160 or gp41. A positive HIV-2 sample requires the two HIV-2 bands being reactive. Other band reactivity patterns indicate an indeterminate result. In HIV-1 seroconversion panels the Geenius™ HIV 1/2 Assay was found to become positive earlier than a comparator WB, due to increased sensitivity for the detection of antibodies to gp41, with a similar sensitivity for the detection of antibodies to gp160. Indeterminate results in those either undergoing seroconversion, in late-stage HIV infection undergoing seroreversion, or not HIV-infected is recognised. Comparative performance with WB has shown excellent results with reduced rates of indeterminate status21. A WHO analysis has shown 100% sensitivity with 97% specificity23.

### Western blot immunoassay

The commonly used WB is a commercial HIV-1 WB which detects antibodies to individual HIV-1 antigens and includes an antigen strip for HIV-2 detection. Specific HIV-2 WBs are available in some reference laboratories.

Western blot HIV-1 assays detect antibodies in patient sera to a larger number of HIV-1 viral proteins than the Geenius™ HIV 1/2 Assay. These HIV-1 viral proteins represent the structural (gag) proteins p17, p24, p55, the enzyme (pol). proteins p31, p51, p66), and the envelope glycoproteins gp41, gp120, gp160. The individual proteins are separated into bands of distinct molecular weight using protein gel electrophoresis then transferred (blotted) to a solid material (such as nitrocellulose strips). The pre-prepared strips are bathed in patient serum for binding of reactive antibodies to the antigens on the strip. The antibodies in the serum can be identified after the addition of enzyme labelled conjugate and reaction with substrate. Some manufacturers offer automated processing and imaging of results.

The development of a positive WB takes approximately six weeks from infection, although the evolution of the blot pattern is affected by PrEP8 and early primary treatment with antiretroviral drugs. Due to this delay, and the frequency of negative p24 antigen assays in acute HIV infection, confirmation of acute HIV infection can be achieved earlier by HIV NAT. WB patterns of reactivity detected during the immune response that do not meet the criteria for an interpretation of “positive” (often with missing bands) are referred to as indeterminate. Some of these patterns can also be seen in uninfected individuals. In 1992 the Australian National HIV Reference Laboratory in collaboration with state reference laboratories published a classification of the positive, negative and indeterminate WB patterns based on patterns of reaction using the NRL WB.9 This classification had been used since that time throughout Australia and New Zealand, until the introduction of the IVD TGA legislation governing Class 4 IVDs. Previous to the IVD framework, the NRL WB interpretation results were regarded as positive when there was detection of antibodies to all of the three main groups of HIV proteins –one env (gp 160, or gp120, or gp 41), plus 3 other viral specific bands from the gag (p24) and pol (p66 or p51) series. HIV-1 WB-indeterminate patterns were assigned to four groups (1 to 4) which stratified the likelihood of true acute HIV infection. Indeterminate groups 3, and especially 4, WB patterns were seen early in the immune response to HIV, although they could also be seen in uninfected individuals. Conversely, with late-stage disease progression (advanced AIDS), gag antibodies may become undetectable, and the WB pattern may revert from positive to indeterminate group 4, with reappearance of p24 antigen.

Since introduction of the TGA IVD legislation, interpretation of the WB used must follow that recommended by the manufacturer of the ARTG licensed WB assay. If further interpretation is applied to the WB then data must be available to validate the accuracy of the result to TGA IVD class 4 standards. In patients with repeatedly reactive screening and indeterminate WB results, follow up samples should undergo HIV NAT and repeat WB after two weeks for seroconversion. Any positive WB should be confirmed by testing a second sample.

## p24 antigen assays

Dedicated p24 antigen assays were previously used in confirmation algorithms for screening HIV antibody/antigen reactive results but are currently unavailable in Australia. The specificity is insufficiently high for p24 antigen tests to be useful as screening test as the test may generate false positive results in this setting.10 Therefore samples reactive on p24 antigen assays must be retested after neutralisation before the results are reported. Caution should be exercised with very low p24 antigen results as the use of optical density values below the cut-off for calculation of neutralisation can produce false positive neutralisation results. p24 antigen assays are also less sensitive than HIV NAT assays with a longer seroconversion window period. In neonatal infection p24 antigen tests are usually negative until one to three months of age and false negatives are more likely if neonatal antiviral therapy is given. In acute HIV in adults and older children prior to seroconversion, a positive p24 antigen result should be confirmed with repeat testing for seroconversion and detection of HIV nucleic acid.

## Suitable specimens

Serum samples are used routinely for most standard HIV antibody and antigen determinations, although plasma samples are also acceptable. Dried blood spots can be used for diagnosis in children who are less than 18 months old. Differences for eclipse and window periods occur for different analytes (serum, plasma, dried blood spots, urine, oral fluid) with serum being the most reliably short eclipse period. Urine, oral fluid as well as dried blood spot are approved for use in some rapid HIV antibody kits24,25,26.

As per manufacturer’s instructions serum should be promptly separated from the clot/cellular elements and refrigerated at +2 °C to +8 °C. If the test is not performed within seven days, the serum specimens should be frozen at −20 °C or lower. Serum can be transported either at room temperature if it is expected to be processed in four to six hours of collection or refrigerated if transportation takes place within seven days of collection.

## Test performance characteristics

Test specificity depends upon several factors, including pre-test probability, population prevalence and population incidence. The proportion of reactive results that are false are higher in low prevalence populations. Consequently, although they have a have a high specificity (>99.8%), false positive results can occur, albeit infrequently.11 Laboratory confirmation of infection in Australia is therefore required. Factors associated with false positive results include frequent blood transfusion, pregnancy, autoimmune diseases, vaccination, and laboratory errors of procedure or specimen handling.

Factors associated with false negative combo assay results include testing during the window period, immunosuppressed patients and patients receiving post-exposure prophylaxis, patients on PrEP, patients who have advanced HIV infection, as well as laboratory errors.12

Differentiation assay indeterminate results in infected individuals are related to several factors such as early seroconversion, incomplete HIV-1 antibody evolution, cross-reactivity with HIV-2 proteins, and cross reactivity with HIV-1 subtype O proteins. Indeterminate results in uninfected individuals are associated with multiple transfusions, hypergammaglobulinemia, recent vaccination, advanced AIDS and autoimmune diseases.

## Suitable internal controls

Commercial kit and a third party low positive control and negative control should be used in every run as recommended by NPAAC, although the third-party control inclusions are not mandatory. These are in addition to the mandatory use of kit controls.

## Suitable external quality assurance program (QAP) program

QAP programs are provided by the Royal College of Pathologists of Australasia (RCPA) serology quality assurance program (SQAP) and the National Serology Reference Laboratory (NRL).

## HIV nucleic acid testing

Molecular based methods for detection of viraemia are available with qualitative NAT and quantitative molecular methods (such as end point and real time PCR, transcription-mediated amplification) for monitoring of viral load and response to therapies (quantitative) and for diagnosis (qualitative or quantitative). Commercial NAT assays must have a TGA IVD class 4 claim for diagnostic purposes.3 Therefore, for HIV NAT confirmation of a reactive screening test result the use of an HIV NAT assay with a TGA IVD class 4 claim on a dedicated specimen or aliquot that has not been used for other testing is required.

Increasingly, molecular tests (qualitative and quantitative) are requested by clinicians for early detection of HIV infection prior to full seroconversion, to facilitate early antiretroviral therapy1 , to diagnose HIV in infants13 , and for individuals with early antiviral therapy such as PrEP and PEP. Of note, both PrEP and PEP have been demonstrated to also suppress HIV RNA levels. It is therefore recommended that HIV testing is repeated 4 and 8 weeks after cessation of PrEP and PEP. NAT assays able to be performed on small volumes (0.1 mL) of whole blood and dried blood spots are used for diagnosis of HIV in infants, enabling the detection of HIV RNA and proviral DNA.

Quantitative viral load assays determine the amount of HIV-1 RNA circulating in the blood of an infected individual. Differences exist in the absolute copy number generated by different viral load assays. International units (IU/mL) are used to report results where 1IU equates to approximately 0.6 copies to allow comparison between different assays, although ideally, the same assays should be used to follow up an individual’s viral load.

In Australia, the HIV NAT assays available and their TGA IVD class can be found on the ARTG listings through the TGA website.

### Suitable specimens

The viral load tests are most commonly performed on plasma, which is the validated specimen type for nucleic acid detection. For transport and storage of specimens for HIV NAT, adherence to the manufacturer’s instructions is especially important to ensure that RNA degradation does not occur.12

These assays have also been used on serum, CSF, cervical secretion, semen and dried blood spot where clinical need has been indicated, although the manufacturer’s instructions should be reviewed to ensure the assay is validated for use in these specimens. Sample types outside of the scope of the manufacturer’s indications must be validated by the laboratory to class 4 IVD standards.

### Test sensitivity

HIV NAT can detect very low amounts of HIV RNA. The quantitative assays have a large dynamic quantifiable range, depending on the assay, from 20 to 150 copies/mL up to 107 to 108 copies/mL and can detect HIV-1 Group M subtypes A-H and Group O genotypes. Commercial HIV-2 quantitative assays are not available, but in-house HIV-2 viral load assays are available in some reference laboratories.

### Test specificity

Test specificity varies between assays with indicative specificities approaching 100%. To avoid laboratory contamination, dedicated specimens or a dedicated pretest aliquot should be used. Specimens previously used in the serology laboratory should not be then used for HIV NAT. Some HIV NAT may produce false positive results when testing patients who have received CAR T-cell therapy, due to this therapy using a retroviral component. Refer to the HIV NAT manufacturer’s IFU for more details on this.

### Suitable internal controls

High positive, low positive, and negative test kit controls must be used in every run. Internal QC samples should be used regularly to monitor assay performance.

### Suitable external quality assurance program and proficiency testing

These are provided by the RCPA SQAP and the NRL.

### HIV proviral DNA PCR

Although HIV-1 DNA PCR has been used as an investigational tool for more than decade, there is no HIV proviral DNA NAT assay registered on the ARTG. Such an assay is of diagnostic use for the detection of HIV infection in infants born to mothers infected with HIV-1. HIV NAT that use whole blood or dried blood spots detect total (RNA and proviral DNA) HIV nucleic acid and may be a suitable alternative.

## Antiretroviral drug resistance testing

The replication rate of HIV is very high and there is no viral proof-reading during replication, as a result mutations appear readily. Mutations that alter the reverse transcriptase (RT), protease and integrase enzymes may result in antiviral resistance. The resistance profiles are assessed and detected using genotypic methods. Phenotypic testing is restricted to research laboratories. Genotypic drug resistance testing should be performed in treatment naïve patients before initiation of treatment and in cases of virological failure (i.e. failure to decrease the viral load by 1 log after 4 to 6 weeks of treatment) or incomplete viral suppression (undetectable viral load in 4 to 6 months of treatment not achieved).14

### Genotypic HIV drug resistance testing

A genotypic assay provides an indirect measure of drug resistance because it is based on detection of the mutations known to be associated with resistance.7 Sanger-based sequencing methods are commonly used, but more recently, some laboratories have introduced next generation sequencing (NGS) targeting specific regions of the HIV genome or whole genome sequencing to determine drug resistance. Typically, Sanger-based sequencing is only able to identify drug resistant mutants at a threshold of 20% of the virus population. It is important to realise that this detects the dominant viruses circulating in the plasma at the time of testing. Low level viruses with diﬀerent resistance proﬁles may be present in the blood or in proviral DNA which can re-appear once the antiretroviral therapy changes.15 By contrast, NGS is able to detect drug resistant mutants at a threshold of <5%. The improved sensitivity of NGS to detect low frequency mutations may be of relevance in the era of two-drug antiretroviral therapy regimens. In general, both methods require the HIV viral load to be >1000 copies/mL to be successful.

### Phenotypic HIV drug resistance testing

Phenotypic assays are no longer used in routine diagnostic laboratories due to the intense labour involved, long turnaround times, and the requirement of a PC3 facility. Phenotypic assays assess the ability of the virus to grow in various concentrations of a given antiretroviral drug. These assays are currently only available in Australia in clinical trials. They involve the insertion of RT or protease gene sequences into a plasmid vector, then culturing a hybrid virus containing that vector in the presence of antiviral drugs, with comparison to a drug-susceptible wild- type HIV.

### Suitable specimens for genotypic testing

Plasma collected from EDTA or plasma separator tube can be used. The plasma must be separated from the cellular elements within 6 hrs of collection and frozen immediately.

### Utility

Treatment may be altered in the knowledge that a patient is carrying a virus resistant to one or more antiretroviral medications. This leads to improved virological suppression in patients whose therapeutic choices have been guided by the use of resistance testing.

### Suitable external QAP program

Several programs (QCMD and Instand) are offered.

## HIV viral isolation

Although a positive culture provides direct evidence of HIV infection, HIV culture is no longer used for routine diagnosis, as it has long turnaround time, low sensitivity and it is labour-intensive. It was useful before the development of NAT in detecting infection in infants born to mothers with HIV infection. Its use is now confined primarily to research laboratories.

In the assay, patient specimens are first cultured by mixing patient peripheral blood monocyte cells (PBMCs) or serum with PBMCs from healthy donors stimulated with phytohemagglutinin and IL-2. Freshly stimulated donor cells must be added weekly, because HIV-1 causes cell death. Viral growth is detected by the presence of RT or p24 antigen released in the culture supernatant.

## Point of care and self-testing

Rapid POC assays that detect HIV specific antibodies have been available in Australia since 2012, and their use has increased in the past decade, particularly in remote and regional areas of Australia. These assays are designed to be performed in clinical settings outside of a laboratory by a trained user, require less technical expertise to perform and are commonly used to increase HIV testing, particularly in high-risk groups (such as men who have sex with men) that are unwilling (e.g. due to concerns about stigma and discrimination) or unable to access health care facilities. The reduced turnaround times of results compared to standard laboratory-based diagnostic tests also make POC tests attractive in this group.

The TGA approved HIV self-testing in 2018, the approved test uses a finger-prick blood sample. HIV self-testing kits can be obtained on-line or be purchased in Australian pharmacies. POC and self-testing is generally not appropriate in populations with low prevalence or pre-test probability of HIV infection due to the potential for false reactive results. POC and self-tests should be used as screening tests only, and reactive results need to be confirmed using conventional testing. POC and self-tests are not appropriate for testing persons with a seroconversion illness or during the window period of HIV infection as the test may be falsely negative due to the longer serological window period27. The POC assays use either finger-prick capillary blood or saliva. Only POC tests registered on the ARTG can be used, and testing must be conducted under an appropriate framework that ensures the required quality and safety.16 The TGA requires confirmation of positive POC and self-test results by a diagnostic laboratory test.

## Diagnosis of HIV in neonates and children < 18 months of age

HIV infection in neonates or children < 18 months born to HIV-infected mothers cannot be diagnosed by serological tests due to the passively acquired maternal antibodies, which may persist for up to 18 months.17,18 Diagnosis in this period can be established using an HIV NAT assay with a TGA IVD class 4 claim on a dedicated specimen or aliquot that has not been used for other testing. Molecular testing such as proviral HIV DNA testing on whole blood or dried blood spots can be performed if the NAT assay has a TGA IVD class 4 claim. These virological assays are considered to be the reference standard for diagnosis of HIV infection in children younger than 18 months. Testing of cord blood is not recommended as there is a chance of contamination of the cord blood by maternal blood which can lead to false positive results.

In the diagnosis of HIV in neonates, proviral HIV DNA or RNA must be tested at different time points as NAT sensitivity increases with age in infants.19 Regimens include testing at three time points - within the first 7 days of life, at 6 weeks and 3 months.20 A definitive diagnosis of HIV-1 infection can be made on the basis of positive HIV proviral DNA or RNA assay results from two or more separate samples.18 HIV infection can be presumptively excluded based on two negative virological test results, one obtained at 6 weeks and one obtained at 3 months of age. HIV antibody testing is performed at 18 months of age to document the clearance of maternal HIV antibodies (seroreversion) and to confirm the infant’s HIV negative status.

HIV-exposed infants are usually formula-fed in Australia, although breastfeeding for up to six months may be considered in mothers with undetectable viral loads. However, if the infant is still breastfeeding from an infected mother, negative results need to be repeated at 4-6 weeks after cessation of breastfeeding to confirm that the infant is not infected.

## HIV screening in solid organ and blood donors

Traditionally HIV seropositive donors have not been utilized in transplantation, due to the known risk of transmission to the recipient. HIV-1 and HIV-2 serology results are required for all potential donors. HIV transmission from an antibody-negative organ donor can occur if the donor is in the serological window period after infection but prior to development of anti-HIV antibody. Therefore HIV-1 NAT testing is also performed on organ donors and cadaveric tissue donors, as it has been on blood donors for many years. Any positive screening test for either HIV-1 or HIV-2 should be confirmed, as for standard confirmation of HIV infection. Although previously considered a contraindication to transplantation, HIV infection in the recipient is no longer an absolute exclusion as many patients with HIV on effective antiretroviral therapy are living longer and are far less immunocompromised, and end-stage organ failure rather than HIV is their survival-limiting condition.

# Laboratory nomenclature for national data dictionary

|  |  |  |
| --- | --- | --- |
| SNOMED CT code | Concept name | Description |
| 190300005 | Organism | Human immunodeficiency virus |
| 89293008 | Organism | Human immunodeficiency virus type 1 |
| 36115006 | Organism | Human immunodeficiency virus type 2 |
| 86406008 | Disorder | Human immunodeficiency virus infection |
| 315124004 | Procedure | Human immunodeficiency virus viral load |
| 103093008 | Substance | Antigen of Human immunodeficiency virus protein 24 |

# References

1. Duncan D, Duncan J, Kramer B, Nilsson AY, Haile B, Butcher A, Chugh S, Baum P, Aldrovandi GM, Young S, Avery AK, Tashima K, Valsamakis A, Yao JD, Chang M, Coombs RW. 2021. An HIV diagnostic testing algorithmusing the cobas HIV-1/HIV-2 qualitative assay for HIV type differentiation and confirmation. J Clin Microbiol 59:e03030-20. (https://doi.org/10.1128/JCM.03030-20).
2. TGA regulatory framework. https://www.google.com/search?q=TGA+framwork
3. Australian Register of Therapeutic Goods. https://www.tga.gov.au/australian-register-therapeutic-goods
4. Ly D, Laperche S, Brennan C et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004; 122-185.
5. Niederhauser C, Ströhle A, Stolz M, Müller F, Tinguely C. The risk of a second diagnostic window with 4th generation HIV assays: Two cases. J Clin Virol. 2009 Aug;45(4):367-9. doi: 10.1016/j.jcv.2009.05.027. PMID: 19546027.
6. [Requirements for Laboratory Testing of Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) (Third Edition 2013)](https://www1.health.gov.au/internet/main/publishing.nsf/Content/health-npaac-docs-hivhepc.htm) (https://www1.health.gov.au/internet/main/publishing.nsf/Content/health-npaac-docs-hivhepc.htm)
7. [HIV SoNG](https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-HIV.htm)
8. Donnell D, Ramos E, Celum C, Baeten J, Dragavon J, Tappero J, Lingappa JR, Ronald A, Fife K, Coombs RW. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS (London, England). 2017 Sep 10;31(14):200
9. Healey DS et al. HIV-1 western blot: development and assessment of testing to resolve indeterminate reactivity. AIDS 1992; 6:629.
10. Gray ER, Bain R, Varsaneux O, Peeling RW, Stevens MM, McKendry RA. p24 revisited: a landscape review of antigen detection for early HIV diagnosis. AIDS. 2018;32(15):2089-2102. doi:10.1097/QAD.0000000000001982
11. [Alagarraju Muthukumar, Adnan Alatoom, Susan Burns, Jerry Ashmore, Anne Kim, Brian Emerson, Edward Bannister, M. Qasim Ansari, Comparison of 4th-Generation HIV Antigen/Antibody Combination Assay With 3rd-Generation HIV Antibody Assays for the Occurrence of False-Positive and False-Negative Results, Laboratory Medicine, Volume 46, Issue 2, May 2015, Pages 84–89](https://doi.org/10.1309/LMM3X37NSWUCMVRS), (https://doi.org/10.1309/LMM3X37NSWUCMVRS)
12. Carroll K et al. Manual of Clinical Microbiology. 12th ed. Chapter 82.
13. Dunn DT, Brandt CD, Krivine A et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9: F7-11.
14. WHO Guidelines for HIV Diagnosis and Monitoring of Antiretroviral Therapy. 2009. (www.Searo.WHO.int/linkfiles/Publications\_SEA-HLM-382.pdf)
15. ASHM HIV Management in Australasia. A guide for clinical care. https://hivmanagement.ashm.org.au/
16. HIV point-of-care tests: Conditions of approval for supply in Australia https://www.tga.gov.au/hiv-point-care-tests-conditions-approval-supply-australia
17. Mother-to-child transmission of HIV infection. The European Collaborative Study. Lancet 1988; 2: 1039.
18. Read J et al. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007; e1547.
19. Lambert JS, Harris DR, Stiehm ER. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr. 2003;34:512–519
20. Management of Perinatal Infections. Australian Society for Infectious Diseases 2014 (Available at: <https://www.asid.net.au/documents/item/368>).
21. Serhir B, Desjardins C, Doualla-Bell F, Simard M, Tremblay C, Longtin J 2019. Evaluation of the Bio-Rad Geenius HIV 1/2 Assay as Part of a Confirmatory HIV Testing Strategy for Quebec, Canada: Comparison with Western Blot and Inno-Lia Assays. J Clin Microbiol 57:10.1128/jcm.01398-18
22. Kusagawa, S., Kawana-Tachikawa, A., Matsubayashi, K. *et al.* Evaluation of Geenius HIV-1/2 Confirmatory Assay for the confirmatory and differential diagnosis of HIV-1/HIV-2 in Japan and reliability of the Geenius Reader in the diagnosis of HIV-2. *BMC Infect Dis* **21**, 569 (2021). <https://doi.org/10.1186/s12879-021-06291-5>
23. WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Geenius™ HIV 1/2 Confirmatory Assay with Geenius™ HIV 1/2 Confirmatory Controls. 2017. <https://extranet.who.int/prequal/sites/default/files/whopr_files/170317_final_pq_report_pqdx_0181_031_00_v3.pdf>
24. Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo rapid test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol, 2013; 58S: e54–8
25. Duong YT, Mavengere Y, Patel H, et al. Poor performance of the Determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a national household survey in Swaziland. J Clin Microbiol 2014; 52:3743–8.
26. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the Determine HIV-1/2 Ag/Ab combo test. J Infect Dis 2012;205:528–34.
27. Kevin P. Delaney, Debra L. Hanson, Silvina Masciotra, Steven F. Ethridge, Laura Wesolowski, Sherry Michele Owen, Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure, Clinical Infectious Diseases, Volume 64, Issue 1, 1 January 2017, Pages 53–59, <https://doi.org/10.1093/cid/ciw666>

# Glossary

**Ag/Ab – Antigen/Antibody**

**AMR – Antimicrobial resistance**

**ARTG** – Australian Register of Therapeutic Goods

**Biotype** – Strain distinguished from other microorganisms of the same species by its physiological properties or a group of organisms with the same genotype

**CCNA** – Cell cytotoxicity neutralisation assay

**(US) CDC** – Centers for Disease Control and Prevention

**CDNA** – Communicable Diseases Network Australia

**CDS** – Calibrated dichotomous susceptibility

**CIA** – Chemiluminescent immunoassay

**Clade** – Group of organisms composed of a common ancestor and all its lineal descendants

**CLSI** – Clinical and Laboratory Standards Institute

**CSF** – Cerebrospinal fluid

**Ct** – Cycle threshold

**DFA** – Direct fluorescent antibody

**DNA** – Deoxyribonucleic acid

**EDTA** – Ethylenediaminetetraacetic acid

**EIA** – Enzyme immunoassay

**ELISA** – Enzyme linked immunosorbent assay

**EUCAST** – European Committee on Antimicrobial Susceptibility Testing

**HI** – Haemagglutination inhibition

**ICT** – Immunochromatographic test

**IFA** – Immunofluorescent antibody

**IgA** – Immunoglobulin A

**IgG** – Immunoglobulin G

**IgM** – Immunoglobulin M

**IVD (device)** – In vitro diagnostic medical device

**In vitro** – performed in a test tube, culture dish, or elsewhere outside a living organism

**In vivo** – performed or taking place in a living organism

**LAMP** – Loop-mediated isothermal amplification

**LPS** – Lipopolysaccharide

**MALDI-TOF** – Matrix-assisted laser desorption ionization-time of flight

**MAT** – Microscopic agglutination test

**MDST** – Molecular drug susceptibility testing

**MDR** – Multidrug resistant

**MIA** – Microsphere immunoassay

**NAAT** – Nucleic acid amplification test/ing

**NATA** - National Association of Testing Authorities, Australia

**NGS** – Next generation sequencing

**NPAAC** – National Pathology Accreditation Advisory Council

**NRL** – National Serology Reference Laboratory

**PCR** – Polymerase chain reaction

**PC2 laboratory** – Physical containment level 2 laboratory

**PC3 laboratory** – Physical containment level 3 laboratory

**PC4 laboratory** – Physical containment level 4 laboratory

**POC** – Point-of-care

**QAP** – Quality assurance program

**QC** – Quality control

**RAPD** – Random amplified polymorphic DNA

**RCPA** – Royal College of Pathologists of Australasia

**RFLP** – Restriction fragment length polymorphism

**RNA** – Ribonucleic acid

**RT** – Reverse transcriptase

**RT-PCR** – Reverse transcription polymerase chain reaction

**SBT** – Sequence based typing

**Serotype** – Pathogens of the same species that are antigenically different

**SNT** – Serum neutralisation

**STI** – Sexually transmitted infection

**Strain** – Variant that possesses unique and stable phenotypic characteristics

**SQAP** – Serology quality assurance program

**Test sensitivity** – Ability of a test to correctly identify patients with a disease

**Test specificity** – Ability of a test to correctly identify people without the disease

**TGA** – Therapeutic Goods Administration

**VTM** – Viral transport media

**WGS** – Whole genome sequencing

**WHO** – World Health Organization

**WHO CC** – WHO Collaborating Centre

**XDR** – Extensively drug resistant